Kingston Health Sciences Centre Research Institute (KHSC-RI) has launched the first-ever Health Canada-approved clinical trial studying at-home micro-dose use of psilocybin to treat Generalized Anxiety Disorder (GAD).
The Phase 2a study will recruit 60 adults with GAD to test whether daily, non-hallucinogenic doses of psilocybin can safely and effectively ease anxiety symptoms. Participants will take the treatment at home for four weeks, followed by an extension or placebo.
“This represents a major shift — a new way of targeting anxiety without sedation or emotional numbing,” said Dr. Claudio Soares, principal investigator at KHSC-RI.
GAD affects more than 1.6 million Canadians, and many patients face limited treatment options.
Supported by Southeastern Ontario Academic Medical Organization and Diamond Therapeutics, the trial marks a milestone in mental health research.
People living with GAD who want to learn more or participate can contact the research team by email.
Story by Alyssa Brush
Tourism Kingston lobbying for a high-speed rail stop in the city
A decision’s been made about local Public Health satellite sites
Kingston hosts Special Olympics basketball with full day of games and prizes
Winter makes an unwelcome return after brief taste of milder weather in Kingston
It's budget time in Kingston
